Advertisements

Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant

Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant.....»»

Category: press-releasesSource: businesswireindiaJul 12th, 2018

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve.....»»

Category: press-releasesSource: businesswireindiaJul 25th, 2018

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting.....»»

Category: press-releasesSource: businesswireindiaJun 24th, 2017

New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis

New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis.....»»

Category: press-releasesSource: businesswireindiaJul 19th, 2018

Lupin to file application for biosimilar etanercept in EU, Japan in next quarter

Lupin to file application for biosimilar etanercept in EU, Japan in next quarter.....»»

Category: featuresSource: livemintFeb 7th, 2018

Lynparza (olaparib) Maintenance Treatment Offers Sustained Quality of Life alongside Improved Progression-Free Survival in Women with BRCA-Mutated Ovarian Cancer

Lynparza (olaparib) Maintenance Treatment Offers Sustained Quality of Life alongside Improved Progression-Free Survival in Women with BRCA-Mutated Ovarian Cancer.....»»

Category: press-releasesSource: businesswireindiaJun 3rd, 2017

Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its primary endpoint

Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its primary endpoint.....»»

Category: press-releasesSource: businesswireindiaJul 20th, 2018

Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma

Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma.....»»

Category: press-releasesSource: businesswireindiaJun 2nd, 2018

Buy Vedanta, target Rs 425: Sumit Bilgaiyan

Buy Vedanta, target Rs 425: Sumit Bilgaiyan.....»»

Category: topSource: moneycontrolApr 12th, 2018

Merck KGaA, Pfizer"s immunotherapy fails in lung cancer trial

Merck KGaA, Pfizer"s immunotherapy fails in lung cancer trial.....»»

Category: global-financeSource: reutersFeb 15th, 2018

Dr. Reddy’s unveils cancer drug in U.S.

Dr. Reddy’s unveils cancer drug in U.S......»»

Category: topSource: the-hinduDec 26th, 2017

Infra sector returning to normalisation post temporary blips: CMIE

Infra sector returning to normalisation post temporary blips: CMIE.....»»

Category: topSource: moneycontrolDec 14th, 2017

Glenmark completes phase 3 study for nasal spray

Glenmark completes phase 3 study for nasal spray.....»»

Category: topSource: moneycontrolDec 14th, 2017

Glenmark Pharma announces results from phase 3 safety study evaluating Ryaltris

Glenmark Pharma announces results from phase 3 safety study evaluating Ryaltris.....»»

Category: topSource: moneycontrolDec 13th, 2017

Post-operative care is key to a successful kidney transplant

Post-operative care is key to a successful kidney transplant.....»»

Category: economySource: business-standardNov 25th, 2017

First ever attempt to edit genes inside human body carried out in the US

First ever attempt to edit genes inside human body carried out in the US.....»»

Category: topSource: moneycontrolNov 17th, 2017

Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma

Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma.....»»

Category: press-releasesSource: businesswireindiaNov 17th, 2017

Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 28th, 2017

Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 28th, 2017

Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.....»»

Category: press-releasesSource: businesswireindiaOct 4th, 2017

Pfizer, Astellas prostate cancer drug clears late-stage trial

Pfizer, Astellas prostate cancer drug clears late-stage trial.....»»

Category: topSource: economictimesSep 14th, 2017